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Abstract
Background: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is an effective technique for
providing emergency mechanical circulatory support for patients with cardiogenic shock. VA-ECMO enables a rapid
restoration of global systemic organ perfusion, but it has not been found to always show a parallel improvement in
the microcirculation. We hypothesized in this study that the response of the microcirculation to the initiation of
VA-ECMO might identify patients with increased chances of intensive care unit (ICU) survival.
Methods: Twenty-four patients were included in this study. Sublingual microcirculation measurements were
performed using the CytoCam-IDF (incident dark field) imaging device. Microcirculatory measurements were
performed at baseline, after VA-ECMO insertion (T1), 48–72 h after initiation of VA-ECMO (T2), 5–6 days after (T3),
9–10 days after (T4), and within 24 h of VA-ECMO removal.
Results: Of the 24 patients included in the study population, 15 survived and 9 died while on VA-ECMO. There was
no significant difference between the systemic global hemodynamic variables at initiation of VA-ECMO between
the survivors and non-survivors. There was, however, a significant difference in the microcirculatory parameters of
both small and large vessels at all time points between the survivors and non-survivors. Perfused vessel density
(PVD) at baseline (survivor versus non-survivor, 19.21 versus 13.78 mm/mm2, p = 0.001) was able to predict ICU
survival on initiation of VA-ECMO; the area under the receiver operating characteristic curve (ROC) was 0.908
(95 % confidence interval 0.772–1.0).
Conclusion: PVD of the sublingual microcirculation at initiation of VA-ECMO can be used to predict ICU mortality
in patients with cardiogenic shock.
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Background
Cardiogenic shock (CS) has a high mortality rate and is de-
fined as a state of tissue hypoperfusion induced by cardiac
failure [1, 2]. Many conditions, such as acute myocardial
infarction [3], end-stage dilated cardiomyopathy [4], myo-
carditis [5], complications following cardiac surgery [6],
and cardiac arrest [7], can cause CS. Veno-arterial extracor-
poreal membrane oxygenation (VA-ECMO) is an effective,
portable, and rapidly deployable technique for providing
emergency mechanical circulatory support for patients in
CS [8–10], and it successfully reduces the time required for
cardiac recovery [11]. Following this bridge therapy, some
patients require implantation of a left ventricular-assist de-
vice (LVAD) or heart transplantation for adequate recovery
and survival. Being able to identify hemodynamic variables
related to survival could provide an important therapeutic
window for optimizing VA-ECMO support. Until recently,
lactate values have been suggested to predict outcomes of
adult and pediatric patients on VA-ECMO [12–14]. How-
ever, these are downstream parameters and do not provide
a direct hemodynamic endpoint.
Evaluation of systemic hemodynamic parameters, such
as blood pressure, cardiac output, and mixed venous sat-
uration, assist in diagnosing CS. VA-ECMO can quickly
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restore global hemodynamics. However, there is no guar-
antee that restoring these systemic hemodynamic vari-
ables will also improve microcirculatory and tissue
perfusion, which is considered the ultimate success of
resuscitation. Many studies have demonstrated that al-
tered microcirculatory functional parameters can be a
good predictor of mortality, despite normalized systemic
hemodynamic variables [15–18]. The use of an intra-
aortic balloon pump (IABP) did not affect the microcir-
culation parameters in these patients with or without
VA-ECMO while restoring the macrocirculation [19, 20].
However, to date, no study has evaluated the sublingual
microcirculatory response of patients with CS on VA-
ECMO in relation to intensive care unit (ICU) outcomes
after VA-ECMO. In this study, we tested the hypothesis
that assessment of the microcirculation at initiation of
VA-ECMO may identify patients with increased chances
of ICU survival. To test this hypothesis we measured
sublingual microcirculation in CS patients eligible for
VA-ECMO therapy using hand-held microscopy.
Methods
Study setting and population
This study was conducted between September 2014 and
October 2015 at the ICU of the Erasmus Medical Center
Rotterdam, The Netherlands. All consecutive patients re-
quiring VA-ECMO for CS were included in the study with
the exception of two patients who died within 24 h for
whom it was not possible to measure microcirculation
due to continuous resuscitation in an overcrowded ICU
box and for four patients who did not consent to inclusion
in the study. Survival was defined as discharge from the
ICU without a need for re-admission or re-implantation
of the VA-ECMO after explantation. Additionally, bridged
patients with durable LVADs or cardiac transplantations
were documented as survivors. Non-survivors were those
who died in the ICU during VA-ECMO support or within
a couple of hours of explantation of VA-ECMO.
The following data were recorded at ICU admission:
age, gender, body mass index, Sequential Organ Failure
Assessment (SOFA) score [21], Acute Physiology and
Chronic Health Evaluation (APACHE) II score, indica-
tions for VA-ECMO, heart rate, mean arterial pressure,
lactate, hemoglobin (Hb), hematocrit (Htc), platelet
count, lactate dehydrogenase (LDH), free hemoglobin
(free-Hb), N-terminal of the prohormone brain natri-
uretic peptide (NT-proBNP), high sensitive troponin T
(HsTnT), creatine kinase (CK), MB fraction of creatine
kinase (CK-MB), and echocardiographic parameters.
VA-ECMO circuit and placement, and patient
management under VA-ECMO
VA-ECMO consisted of polyvinyl chloride tubing, a
membrane oxygenator (Quadrox Bioline; Jostra-Maquet,
Orleans, France), a centrifugal pump (Rotaflow; Jostra-
Maquet), and either percutaneous arterial and venous
femoral, or central right atrial and aortic cannulae (Bio-
medicus Carmeda; Medtronic, Boulogne-Billancourt,
France). An oxygen-air blender (Sechrist Industries,
Anaheim, CA, USA) ventilated the membrane oxygen-
ator. Because of the percutaneous femoral VA-ECMO,
an additional 7-F cannula was inserted distally into the
femoral artery to prevent severe leg ischemia. Patients
were kept on VA-ECMO for at least 48 h. The circuit
was checked daily for significant fibrin deposition or
clots accumulated on the membrane during hemolysis,
thrombocythemia, or a sharp and systematic decline
after blood oxygenation by experienced perfusionists
and changed according to protocol.
Microcirculatory measurements
Microcirculation measurements were performed using a
CytoCam imaging device (CytoCam; Braedius Medical,
Huizen, The Netherlands), which is a third-generation
hand-held microscope [22]. The CytoCam device has a
computer-controlled, high-resolution image sensor. Add-
itionally, a CytoCam-IDF (incident dark field) device has a
specifically designed microscopic lens that produces high-
resolution images, showing approximately 30 % more ca-
pillaries than previous-generation devices [22–24]. The
newly introduced lightweight (140 g versus previous de-
vices weighing approximately 450 g) Cytocam-IDF device
(with improved optics, a computer-controlled image sen-
sor and illumination, and a more precise focusing mech-
anism) used in the present study allows for a faster and
more stable and precise measurement to be made. In
addition to these improvements, the device also has a fas-
ter measurement acquisition time, requiring only 3 to 5 s
to assess the quality of the microcirculation. The suffi-
ciency of this time was agreed upon in the second consen-
sus conference held recently in November 2015 in
Amsterdam and in March 2016 in Brussels, where most of
the practitioners used the new Cytocam-IDF technology
evaluated in the present study. Without applying pressure,
the tip of the light guide is gently placed on the mucosal
surface of the sublingual area. A 3- to 5-s video recording
of predefined (left, right, and midline sublingual cavity)
sites was obtained in each patient. Recordings were then
blinded and analyzed to obtain the following microcircula-
tory parameters: total vessel density (TVD; mm/mm2),
perfused vessel density (PVD; mm/mm2), proportion of
perfused vessels (PPV; %), and microvascular flow index
(MFI; arbitrary units (AU); a semiquantitative measure of
microcirculatory flow [25]). Microcirculatory measure-
ments were repeated at the following time points: base-
line, after VA-ECMO insertion within 24 h (T1), 2–3 days
after initiation of VA-ECMO (T2), 5–6 days after initiation
of VA-ECMO (T3), 9–10 days after initiation of VA-
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ECMO (T4), and within 24 h of explantation of VA-
ECMO. The timing between VA-ECMO insertion and the
first microcirculatory and echocardiography measure-
ments are shown in Table 1. The first echocardiography
measurement was performed after a median of 9 (range
1–23) h and the microcirculatory measurement was per-
formed after a median of 15 (range 1–22) h. Image clips
were included which confirmed a quality score defined by
Massey et al. [26]. Thus, 154 clips of 335 were excluded,
and 181 clips were analyzed. Details of the excluded and
included clips and the number of patients at each time
point are shown in Additional file 1: Table S5. The most
important reason for the poor quality of the clips was
patient-related clinical conditions (such as bleedings, sal-
iva, difficulty opening the mouth, difficulty inserting the
device appropriately due to an endotracheal or gastric
tube, and the lack of patient cooperation), especially in
explanted patients. In addition, device-related conditions
such as difficulties with focusing, brightness, and pressure
artefacts resulted in poor-quality clips. Image clips were
randomized and blinded to the three investigators (AK,
SA, WdW) who performed the analysis using software to
calculate the various functional microcirculatory parame-
ters [27]. Microcirculatory parameters were divided into
two categories: small vessels, defined as having a diameter
of 25 μm or less (for example, TVD small vessel, PVD
small vessel); and all vessels, defined as having small ves-
sels and large vessels (>25–100 μm diameter; TVD all ves-
sel, PVD all vessel) according to the consensus on
microcirculatory assessment by De Backer et al. [25].
Statistical analyses
Categorical variables are presented as frequencies and per-
centages. Continuous variables are presented as medians
and range. Continuous variables were compared using a
Mann–Whitney U test. For comparisons of microcircula-
tory parameters of patients in the same group at consecu-
tive time points, a Friedman test was used. Baseline PVDs
of all vessels, lactate HsTnT, and left ventricular ejection
fraction (LVEF) were assessed as prognostic tests of sur-
vival using receiver operating characteristic curves (ROC)
and their corresponding area under the curve. Cut-off
points were calculated by obtaining the best Youden index
(sensitivity + specificity – 1). Sensitivity, specificity, and
positive and negative predictive values were calculated
and compared to each other. With the cut-off values, an
association between microcirculatory impairment and sur-
vival was explored. Statistical significance was defined as
p < 0.05. Statistical analyses were performed using SPSS
version 21.0.0.1 (SPSS, IBM, Armonk, NY, USA).
Results
Thirty consecutive patients requiring VA-ECMO for CS
were recruited to the study. Six patients were excluded:
two patients who died within 24 h for whom it was not
possible to measure microcirculation due to continuous
resuscitation in an overcrowded ICU box, and four pa-
tients who did not consent to inclusion in the study. In
total, 24 patients were included in the study.
Of the 24 patients who comprised the study popula-
tion, 15 survived and 9 died on VA-ECMO. Eight pa-
tients were also inserted with an IABP in addition to
VA-ECMO (two patients in the survival group (IABP was
placed before ECMO), and six patients in the non-survival
group received IABP (4 patients before ECMO and 2 pa-
tients during ECMO support)). The baseline characteris-
tics, baseline global hemodynamics, and microcirculatory
parameters are shown in Table 1. The median ages of the
patients in the survivor and non-survivor groups were 51
(range 23–70) and 51 (20–67), respectively. The number
of males was higher in the survivor group (n = 12; 80 %)
compared to the non-survivor group (n = 4; 44 %). The
APACHE II scores (31 (19–45) and 34 (29–44), respect-
ively), SOFA scores (10 (4–20) and 12 (2–15), respect-
ively), and systemic hemodynamics were not significantly
different between the groups. The use of vasopressors and
inotropic drug doses and blood transfusions did not statis-
tically differ between groups on the first day of VA-ECMO
or during VA-ECMO (Additional file 2: Table S6). Sys-
temic hemodynamic variables, such as the lactate and
hemoglobin values at the microcirculatory measurement
time points, did not differ between survivors and non-
survivors (Additional file 2: Table S6 and Additional file 3:
cardiac output ROC, curve 5). While the cardiac output at
baseline was statistically significantly different between the
groups, the predictive value for ICU survival is less signifi-
cant than the PVD measured sublingually. The cardiac
function assessed by echocardiography was comparable
between the groups, except for the LVEF 20 (8–55) and
10 (7–20); p = 0.010). The heart function biomarkers also
showed no differences between the survivors and non-
survivors. However, the baseline troponin levels at the ini-
tiation of VA-ECMO (1683 (45–42,813) ng/L and 13,369
(215–89,641) ng/L; p = 0.030) were significantly higher in
the non-survivors. The ICU and hospital durations of stay
were significantly different between the groups (18 (6–65)
and 5 (2–36); and 22 (6–72) and 5 (2–36) days for
survivors and non-survivors, respectively). The total
number of days on VA-ECMO was similar for the
survivor and non-survivor groups.
As shown in Fig. 1, the microcirculatory parameters at
the initiation of VA-ECMO were significantly lower in the
patients who subsequently did not survive compared to
those who survived. The comparisons of measured micro-
circulatory parameters are shown for all time points in
Additional file 4: Table S2. The microcirculatory parame-
ters at T1 (i.e., the TVD, PVD, and PPV values) were sig-
nificantly different between the survivor and non-survivor
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Table 1 Patient baseline characteristics
Demographics Total (n = 24) Survivors (n = 15) Non-survivors (n = 9) P valuea
Age (years) 56 (20–70) 51 (23–70) 51 (20–67) 0.244
Male gender (n (%)) 16 (67) 12 (80) 4 (44) 0.08
BMI (kg/m2) 24.5 (19–37) 25.0 (19–37) 24.0 (20–37) 0.904
SOFA score on admission day 11 (2–20) 10 (4–20) 12 (2–15) 0.309
APACHE II 32 (19–45) 31 (19–45) 34 (29–44) 0.244
VA-ECMO indications
Dilated cardiomyopathy 1 0 1 ns
Ischemic cardiomyopathy 2 1 1 ns
Fulminant myocarditis 1 0 1 ns
Intoxication 1 1 0 ns
Pulmonary embolism 1 1 1 ns
Drowning 1 1 0 ns
Post-cardiectomy 5 4 1 ns
Cardiac arrest (n (%)) 12 (50) 8 4 0.680
IHCA 4 3 1
OHCA 8 5 3
Global hemodynamics at admission
Heart rate (beats/min) 93 (50–185) 91 (50–128) 95 (64–185) 0.858
MAP (mmHg) 67 (15–103) 71 (49–98) 66 (15–103) 0.269
Lactate (mmol/L) 4.1 (1.1–26) 4.0 (1.20–26) 6.2 (1.1–18) 0.743
Hb (mmol/L) 6.0 (4.7–11.3) 6.2 (4.7–11.30) 5.7 (5.0–7.9) 0.152
Htc (L/L) 0.32 (0.23–0.50) 0.30 (0.27–0.50) 0.28 (0.23–0.39) 0.100
Platelet count (1000/mm3) 136 (18–336) 136 (64–336) 148 (18–227) 0.835
LDH (U/L) 888 (264–16,779) 810 (264–16,779) 973 (360–3863) 0.493
Free-Hb (mg/dl) 4 (1–640) 4 (1.0–640) 4 (1.0–17) 0.516
HsTnT (ng/L) 4657 (45–89,641) 1683 (45–42,813) 13,369 (215–89,641) 0.030
CK (U/L) 2771 (27–18,526) 1082 (223–7286) 2637 (27–18,526) 0.114
CKMB (μg/L) 45.8 (1.2–859) 36.9 (2.5–412.1) 226 (1.2–859) 0.233
VA-ECMO flow (L/min) 4.14 (2.40–6.30) 4.0 (2.40–6.30) 4.1 (3.30–4.70) 0.929
Timing between VA-ECMO insertion and first microcirculation
measurement (h)
15 (1–22) 15 (2–22) 13 (1–21) 0.857
Timing between VA-ECMO insertion and first echocardiography
measurement (h)
9 (1–23) 7 (1–23) 11 (3–21) 0.426
Echocardiographic parameter at first 24 h after VA-ECMO
implantation
Aortic VTI (cm) 7 (5–22) 8,5 (5–22) 6 (5–12) 0.220
LVEF (%) 15 (7–55) 20 (8–55) 10 (7–20) 0.010
TDSab (cm/s) 5 (5–7) 5 (5–7) 5.5 (5–6) 1
TAPSE (cm) 10 (8–20) 10 (8–15) 8 (8–20) 0.845
Global hemodynamic parameters at first 24 h after VA-ECMO
implantation
COc (L/min) 2.1 (0.75–5.73) 2.46 (0.75–5.73) 1.37 (0.97–4.0) 0.035
CId (L/min/m2) 1.1 (0.39–2.81) 1.23 (0.39–2.81) 0.74 (0.48–1.69) 0.069
DO2
e (ml O2/min) 289 (122–790) 327 (150–790) 174 (122–510) 0.006
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groups (all vessels p = 0.008, p = 0.001, and p = 0.044, re-
spectively; small vessels p = 0.009, p = 0.003, and p = 0.038,
respectively). The microcirculatory values decreased in
both groups 3 days after the initiation of VA-ECMO at T2
in parallel with a reduction in arterial Hb, which is associ-
ated with hemodilution. Although the microcirculatory
parameters of the non-survivor group somewhat recov-
ered at day 6 (T3), they remained significantly lower than
those in the survivor group (Fig. 2; Additional file 5: Table
S3). All the non-survivors passed away while on VA-
ECMO, whereas additional microcirculation was observed
in the survivors following weaning from VA-ECMO. The
microcirculatory parameters of the survivors then became
slightly lower upon removal of VA-ECMO compared to
their values while still on VA-ECMO (Fig. 2). Notably,
the microcirculatory parameter values did not signifi-
cantly change in time when on VA-ECMO. This effect
was observed in both the survivors and non-survivors
(Additional file 5: Table S3) and is shown in Fig. 3, where
no difference in the VA-ECMO blood flow was observed
between the initiation of VA-ECMO and all the other time
points between the both groups. None of the surviving pa-
tients were bridged to a cardiac transplantation or LVAD
in this period.
To compare the sensitivity and specificity of the microcir-
culatory parameters for PVD in all vessels, LVEF, HsTnT,
and lactate at the moment of initiation of VA-ECMO and at
T1 were evaluated with ROC curve analysis to differentiate
these values between the survivors and non-survivors
(Fig. 4). The areas under the ROC curves (and the 95 % con-
fidence interval) were 0.908 (0.772–1.0), 0.847 (0.672–1.0),
0.755 (0.524–0.986), and 0.556 (0.300–0.813) in the survi-
vors and non-survivors, respectively. According to the ROC
curve analysis, the threshold value of PVD for all the vessels
Table 1 Patient baseline characteristics (Continued)
Fluid balance 1.35 (–1.90 to 4.00) 1.50 (–1.90 to 3.80) 1.0 (–1.10 to 4.0) 0.590
CVP (mmHg) 12 (1–32) 12 (1–32) 12 (5–17) 0.726
Microcirculation at first 24 h after VA-ECMO implantation
All
TVD (mm/mm2) 17.13 (11.88–30.39) 20.07 (15.71–30.39) 14.92 (11.88–23.99) 0.008
PVD (mm/mm2) 16.32 (11.01–29.60) 19.21 (12.99–29.60) 13.78 (11.01–18.47) 0.001
PPV (%) 96.48 (76.99–100) 98.06 (76.99–100) 89.20 (77–100) 0.044
MFI (AU) 2.97 (1.75–3.0) 3.0 (2.50–3.0) 2.87 (1.75–3.0) 0.191
Small
TVD (mm/mm2) 15.70 (10.91–29.62) 18.85 (12.80–29.62) 11.84 (10.91–20.32) 0.009
PVD (mm/mm2) 14.16 (9.80–28.23) 18.61 (9.80–28.83) 11.01 (10.13–16.89) 0.003
PPV (%) 96.45 (43.59–100) 97.97 (76.46–100) 89.77 (82.93–100) 0.038
MFI (AU) 3 (0.75–3.0) 3.0 (2.25–3.0) 3.0 (0.75–3.0) 0.084
Outcome
Total days on VA-ECMO (days) 5.5 (2–36) 6 (2–21) 5 (2–36) 0.588
ICU length of stay (days) 13.5 (2–65) 18 (6–65) 5 (2–36) 0.03
VA-ECMO-free days on ICU (days) 2.5 (0–52) 10 (0–52) 0 0.0000
Hospital length of stay (days) 17 (2–72) 22 (6–72) 5 (2–36) 0.01
ICU mortality (n (%)) 9 (37.5) 0 9
Hospital mortality (n (%)) 11 (45.8) 2 9
Categorical variables are presented as frequencies and percentages (n (%)) where stated; all other (continuous) variables are presented as median (range)
APACHE Acute Physiology and Chronic Health Evaluation, AU arbitrary units, BMI body mass index, BSA body surface area, CI cardiac index, CK creatine kinase,
CK-MB myoglobin fraction of creatine kinase, CO cardiac output, CVP central venous pressure, DO2 oxygen delivery, free-Hb free hemoglobin, Hb hemoglobin,
HsTnT high sensitive troponin T, Htc haematocrit, ICU intensive care unit, IHCA in-hospital cardiac arrest, LDH lactate dehydrogenase, LVEF left ventricular ejection
fraction, LVOT left ventricular outflow tract, MAP mean arterial pressure, MFI microvascular flow index, OHCA out-of-hospital cardiac arrest, PaO2 arterial oxygen
tension, PPV portion of perfused vessels, PVD perfused vessel density, SaO2 arterial oxygen saturation, SOFA Sequential Organ Failure Assessment, TAPSE Tricuspid
annular plane systolic excursion, TDSa spectral tissue Doppler imaging mitral annulus peak systolic velocity, TVD total vessel density, VA-ECMO veno-arterial extra-
corporeal membrane oxygenation, VTI velocity time integral
aA Mann Whitney U test was used for comparison between the survivor and non-survivor groups; significant results are shown in bold text
bTDSa was only retrospectively found in 7 of the 24 patients’ echocardiography
cCO = heart rate × stroke volume, where stroke volume = LVOT area × LVOT VTI, and LVOT area was calculated by two-dimensional echocardiography using the
following formula: (π × (LVOT diameter/2)2 (45)
dCI = CO/BSA, where BSA (in m2) was calculated according to the formula (by DuBois and DuBois) BSA = 0.20247 × height (m)0.725 × weight (kg)0.425
eDO2 = CO × CaO2 × 10, where CaO2 = (Hb × 1.34 × SaO2) + (PaO2 × 0.003); 0.003 is the solubility coefficient of oxygen in human plasma; each gram of hemoglobin
is capable of carrying 1.34 mL of oxygen, and the amount of oxygen carried on the haemoglobin is Hb × 1.34 × SaO2
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was 15.2 (mm/mm2) and was found to predict ICU survival
(sensitivity 88.9 %, specificity 86.7 %, positive predictive
value 80 %, negative predictive value 92.9 %, and Youden
index 0.75; Additional file 6: Table S4, Additional file 7,
Additional file 8).
Discussion
This prospective, observational, single-center study on pa-
tients with cardiogenic shock requiring VA-ECMO circu-
latory support showed that ICU survival could be
predicted by observation of poor microcirculatory
function at the initiation of VA-ECMO. Our study further-
more showed that VA-ECMO in itself did not change the
physiological condition of the microcirculation through-
out the course of VA-ECMO. These results suggest that
assessment of sublingual microcirculation at initiation of
VA-ECMO can be used to predict survival. While most of
the differences are observed at baseline, changes over time
seem less relevant. This seems to reflect more what oc-
curred before, rather than during, ECMO. It also charac-
terizes VA-ECMO as a bridge-to-treat procedure not
contributing to resolving cardiac dysfunction following
Fig. 1 a Microcirculatory measurements showing the median and interquartile range between the survivors (S) and non-survivors (NS) for a all vessels
and b small vessels at the initiation of the VA-ECMO insertion (T1), 48–72 h after VA-ECMO initiation (T2), and 5–6 days after VA-ECMO initiation (T3).
AU arbitrary units, MFI microvascular flow index, PPV proportion of perfused vessels, PVD perfused vessel density, TVD total vessel density
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CS. From these considerations it could be argued that our
results lay the foundation for introducing new adjunct
therapeutic modalities aimed at improving microcircula-
tory function during the course of VA-ECMO, which may
improve the chances of successful weaning from VA-
ECMO and survival. Finally, our study suggests that
microcirculatory monitoring could provide an easy tool to
help the intensivist make the clinical decision to initiate or
escalate further treatment options in patients with cardio-
genic shock.
To date, several studies have evaluated predictors of
outcome at the time of VA-ECMO initiation for CS.
Schmidt et al. [28] described the value of pre-VA-
ECMO implantation factors for predicting survival in
cardiogenic shock patients receiving VA-ECMO on
which they formulated a survival after VA-ECMO
(SAVE) score. They found that this SAVE score could
predict survival in these patients. Van Genderen et al.
[29] investigated sublingual microcirculatory and per-
ipheral tissue perfusion parameters in relation to sys-
temic hemodynamics during and after therapeutic
hypothermia following out-of-hospital cardiac arrest.
They found that microcirculatory parameters were
significantly lower in non-survivors at hospital admis-
sion and after rewarming than survivors. Microcircu-
latory alterations were also associated with organ
failure and death, independent of changes in systemic
hemodynamic parameters [29]. Aissaoui et al. [30] in-
vestigated predictors of successful VA-ECMO weaning
after assistance for refractory CS. They described a
number of echo criteria predictive for successful
weaning. However, their study did not describe any
predictors for patient survival. In this study, we found
that baseline perfused vessel density is the best micro-
circulatory parameter predictive of ICU survival. Ob-
servation of low PVD measurements at initiation of
VA-ECMO could lead to earlier initiation of advanced
therapies such as LVAD or heart transplantations.
Another study we performed in pediatric ECMO pa-
tients [31] showed that patients who responded to ECMO
with improved microcirculation went on to survive,
whereas those that did not failed to survive.
Fig. 2 Example of change in the perfused vessel density (PVD) parameters in the survivor (S) and non-survivor (NS) groups at the following time
points: initiation of the VA-ECMO insertion (T1), 48–72 h after VA-ECMO initiation (T2), 5–6 days after VA-ECMO initiation (T3), and after VA-ECMO
explantation (Texp). The medians are depicted
Fig. 3 VA-ECMO blood flow showing the median and interquartile
range between the survivors (S) and non-survivors (NS) at the initiation
of the VA-ECMO insertion (T1), 48–72 h after VA-ECMO initiation (T2),
and 5–6 days after VA-ECMO initiation (T3). ECMO extracorporeal
membrane oxygenation
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A surrogate biomarker for left ventricular function
was measured in our study. HsTnT was also found to be
a good predictor for survival in the ROC analysis we
performed. The study by Luyt et al. [32] assessed the
predicative value of biomarkers for the prediction of car-
diac recovery in patients on VA-ECMO who had not
been investigated for HsTnT. However, their study in-
vestigated troponin Ic, which may have been the reason
why they had found no relationship between cardiac bio-
markers and cardiac recovery in VA-ECMO. Apart from
HsTnT, LVEF was found to be the second best predictor
for survival in the ROC analysis we performed. However,
after initiating VA-ECMO, the heart is artificially
bypassed and the cardiac output and ejection fraction
are influenced by VA-ECMO. Thus, the echocardiog-
raphy is affected by several factors such as aortic valve
regurgitation, the aortic valve opening ratio, afterload
change, and the VA-ECMO flow. In addition, transtho-
racic echocardiography is poor in quality, and trans-
esophageal echocardiography is a less reliable ejection
fraction measurement during VA-ECMO, which affects
the measurement of the LVEF. However, even though
the above parameters were related to the outcome to
various degrees, our ROC analysis identified microcircu-
latory alterations measured on day 1 as having the high-
est specificity and sensitivity of all parameters measured
for predicting mortality in the ICU.
In our observational study, volume status was mainly
assessed by echocardiography and general hemodynamic
parameters, such as the central venous pressure (CVP).
We found no statistical significance between the two
groups regarding the associations between fluid balance
and CVP in the first 24 h and the outcome. It is worth
pointing out, however, that even though the assessment
of volume in non-VA-ECMO critically ill patients has
extensively been studied and included in guidelines, ac-
curate assessments of volume status in patients on
ECMO with altered circulatory conditions (e.g., the pres-
ence of extracorporeal circulation and by-passing differ-
ent parts of the endogenous circulation) is a subject in
need of further investigation.
Our findings highlight the fact that ECMO is not a
therapy that improves patient outcomes but rather it is a
bridge to treatment. Our findings therefore identify a
mean of 5 days as a window for treatment. It also means
that additional therapeutic modalities targeting the
microcirculation need to be developed for inclusion in
the ECMO procedure, which may then elevate ECMO
from the therapeutic modality status as a bridge to a
treatment.
In the course of VA-ECMO, systemic perfusion is
switched to an extracorporeal circulation, the blood is ex-
posed to non-biocompatible polymers that can activate
blood cells and the coagulation system, and it changes
from a pulsatile to a non-pulsatile flow [33, 34]. While
IABP may provide a pulsatile flow, many studies have
shown that this was of no benefit to the microcirculation
[20, 35, 36]. All of these factors might have detrimental ef-
fects on the microcirculation and may explain why the
microcirculatory parameters decreased from T1 to T2 in
both groups. At the same time, even though the VA-
ECMO flows were similar in both groups, microcirculatory
parameters were absolutely different at all time points.
This means that there was no hemodynamic coherence
Fig. 4 Receiver operating characteristics (ROC) curves showing the relationship between sensitivity and 1 – specificity in determining the perfused
vessel density (PVD) all vessels, high sensitive troponin T (HsTnT), lactate, and left ventricular ejection fraction (LVEF) to predict ICU survival
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between macrohemodynamics and the microcirculation
and that microcirculatory alterations manifest themselves
independently of systemic hemodynamics [37]. Further-
more, differences in microcirculatory measurements be-
tween the groups were observed at all time points, while
persistent microcirculatory derangement was observed in
the non-survivor group. In addition, our study showed that
microcirculation remains high after VA-ECMO explant-
ation in the survivor group.
Our study, however, has some limitations. First, it was
single-center study and concerned a relatively small num-
ber of patients. However, to the best of our knowledge,
this is the largest series of patients investigated on this
topic to date. Second, we included patients who presented
with different kinds of VA-ECMO cardiac injury. There-
fore, these patients may have had different microcircula-
tion properties prior to presentation. Another limitation
was the exclusion of patients dying within 24 h. Fourth,
apart from global hemodynamics, VA-ECMO can ad-
versely affect the microcirculation for many reasons such
as hemodilution, hemolysis, coagulopathy, non-pulsatile
flow, and hypothermia [38]. T1 measurements were per-
formed within 24 h after the initiation of VA-ECMO,
which can be considered a long time period.
The last, but still controversial, limitation is the length
of recording sequences used in our study. The use of a
new generation hand-held microscopy device may have
advantages, but also may have disadvantages. The advan-
tage of the Cytocam IDF camera used in this study is
that images are able to observe more capillaries (30 %)
than the previous-generation sidestream dark field (SDF)
cameras due to improved optics [22, 24]. In combination
with a larger field of view (1.55 × 1.16 mm = about three
times larger than the field of view of previous devices) of
the new generation camera, it could be argued that this
camera provides more accurate information concerning
microcirculation alterations then previous-generation
SDF camera. On the other hand, default Cytocam mea-
surements take between 3- and 5-s recordings which
have been found to be of sufficient length in a large
number of recent studies [22, 39–42]. A recent review
on microcirculation measurements by Massey and
Shapiro [43] also recommended that lengths of between
3 and 5 s are sufficient. However, this length may be
considered too short when comparing it to video se-
quences of 20 s recommended for SDF devices in the
consensus of 2006 [25], although this recommendation
was based on opinion and has never been validated
in the literature. Even for SDF images, it has sug-
gested in a recent experimental study by Kildal et al.
[44] in pigs that measurements up to 10 min pro-
vide extra information. The only way to establish the
sufficient length of the video sequences is to demon-
strate statistical significance between the groups,
which we did for this study. Whether such a length
is sufficient for other applications, however, has to
be investigated.
Conclusion
In our study, altered baseline perfused sublingual micro-
circulatory vessel density was found to be related to ICU
survival in cardiogenic shock patients treated with VA-
ECMO. To our knowledge, this is the first study to de-
scribe such an application in this group of patients.
We conclude that monitoring sublingual microcircula-
tion could be used for earlier identification of patients
who will survive, as well as for exploring the usefulness
of earlier consideration of the utilization of advanced
therapies. Our expectation is that such assessment may
be of value in the early identification of patients at a
high risk of death, or those with poor recovery, and to
potentially develop microcirculatory-targeted recovery
strategies. Further studies with a larger number of pa-
tients and the same etiology of CS are needed.
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